Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo radiation therapy aims to tame large brain tumors

NCT ID NCT07162246

Disease control Sponsor: Sunnybrook Health Sciences Centre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a new way to treat large brain tumors using two different radiation machines. Patients get four daily treatments with a linear accelerator, then a break, followed by one precise Gamma Knife treatment. The goal is to better control tumors while protecting healthy brain tissue. The trial will enroll 60 adults with up to two large brain lesions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Radiation therapy (Gamma Knife and linear accelerator)
What this could lead to
If successful, this could offer a safer, more effective way to treat large brain tumors, reducing side effects like radiation necrosis.
What could go wrong
This is a small, early-phase trial (60 people) testing a new combination. It may not work better than current methods, and there are still risks of side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jun 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Presence of up to two large intracranial lesions * Up to 10 (previously untreated, or progressing after previous treatment) brain metastases at the time of enrollment on the diagnostic MRI (which includes the ILLs) to be treated with SRS/HSRS * Age =\> 18 years * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Expected survival \>3 months * Patients that are deemed suitable for both GK and Linac based treatment * Patients that are able to hold systemic cancer chemotherapy/immunotherapy at least 2 days prior and following an SRS fraction Exclusion Criteria: * Prior SRS to the ILLs * Prior WBRT, or plan for concurrent WBRT with the protocol treatment * Presence or history of any leptomeningeal/pachymeningeal disease * Metastatic disease within the ventricles of the brain or corpus callosum * Small cell, hematopoietic or germ cell primaries * Patient with absolutely contraindications for MRI * Severe symptoms that preclude MRI or treatment using standard procedures for Linac or GK * Pregnant or lactating patient * Inability or unwillingness to undergo informed consent or post-treatment follow-up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain (nervous system) cancers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer metastatic malignant neoplasm in the brain neoplasm Neurologic Manifestations Silver-Russell syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain (nervous system) cancers Brain metastasases SRS

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sunnybrook Health Sciences Centre

    RECRUITING

    Toronto, Ontario, M4N3M5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.